CRL Trading Analysis - 10/23/2026 04:21 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for Charles River Laboratories (CRL) includes the following thematic headlines and catalysts that may relate to the embedded data:

• CRL rallied sharply in mid-October on renewed biopharma outsourcing demand and positive sector commentary around clinical trial volumes.
• Concerns emerged over softening margins in the contract research organization (CRO) space amid client funding constraints.
• A recent analyst note highlighted CRL's high beta (1.48) and volatile multiple as a risk into year-end.
• No confirmed near-term earnings date was flagged in the provided data, but fiscal year end is listed as 2025-12-01, suggesting reporting risk ahead.
• Headlines around broad market risk-off could explain the bearish delta-40-60 options flow despite strong price momentum.

This news context is separated from the strict data analysis below, which is based only on the embedded datasets.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 684.90 with trailing EPS of -4.85, indicating the company is currently unprofitable on a trailing basis.
• Forward P/E, PEG ratio, profit margins, revenue growth, ROE, and debt-to-equity are all null — not available in the data.
• Market cap is $16,483,799,310.00 with 47,739,000.00 shares outstanding.
• Dividend yield is 0.00% with no dividend rate or ex-dividend date.
• Beta is 1.48 (above 1.0, suggesting higher volatility than the market).
• 52-week range: low $146.20, high $348.95 — current price near the high end.
• Institutional ownership is 90.41%, showing heavy institutional presence.
• Average volume is 1,037,000.00 vs 20-day avg volume of 742,048.00 in indicators.
• Historical volatility is 44.93%.
• Analyst consensus, target mean price, and recommendation key are null — no analyst target context available.

Fundamentals show negative earnings and an extreme valuation multiple with limited disclosed operating metrics. This diverges from the strong technical uptrend and bearish options sentiment, highlighting a disconnect between price strength and underlying profitability.

Current Market Position

From the embedded data:

• Daily close on 2026-10-22 was $338.74; minute bars show 2026-10-23 15:50 close at $344.70.
• 2026-10-22 daily range: high $351.21, low $337.78, volume 2,124,872 (above 20-day avg of 742,048).
• Minute bars (2026-10-22 09:30 to 2026-10-23 15:50) show opening dip to $339.67 then push to $350.99 by 09:40 on 10-22, fading to $344.70 by last bar.
• Intraday on 10-23 shows narrow range ($344.70–$345.68) with declining volume late session (25,122 at 15:50).

Technical Analysis

• SMAs aligned bullish: 5 > 20 > 50 ($320.42 > $304.24 > $292.78), no bearish crossover.
• RSI 14 at 70.57 is above 70 — overbought momentum signal.
• MACD (11.28) above signal (9.03), histogram positive 2.26 — bullish momentum.
• Price ($338.74) above Bollinger upper ($333.24) — expansion, statistically extended.
• 30-day range: price near top (high $351.21, low $267.27); current near 93rd percentile of range.

True Sentiment Analysis (Delta 40-60 Options)

From CRL_options_20261023_1620.json:

Call Volume: $275,110.00 (24.80%) Put Volume: $835,220.00 (75.20%) Total: $1,110,330.00

• Sentiment: Bearish (put dollar vol 3x calls).
• 74 call contracts vs 135 put contracts; 5 call trades vs 3 put trades.
• Only 8 of 400 options analyzed met delta 40-60 filter (2.0%) — pure directional conviction is bearish.
• Directional puts dominate, suggesting near-term downside expectations despite bullish technicals.

Key Price Levels (Observational Only)